For those of you who follow medical/biotech area, you might want to take a look at NEO. Rapidly growing
diagnostic lab (cancer) company that is firing on all cylinders & largely unknown at the retail level. Compelling story. As always, conduct your own due diligence & come to your own conclusions.
Question: Why would 1st Eagle maintain this losing position for so long? it simply doesn't make sense. It makes me wonder whether the shares are actually "parked" in the fund & controlled indirectly by Roche family as an investment vehicle. On the other hand, why did Fidelity belatedly come to the table? Weird; very weird.
supplying OLED iPhone screens to Apple. "Happy-Talk" on QDOT is just that; they simply can't deliver on OLED TV at this time (and will go full bore to prevent LG or Japan Display from eroding their supply relationship with Apple). They're just putting the best face that they can on their inability to compete in OLED TV at this time.
You likee eat kitty cat? How you say meow, meow? You no likee OLED ("OREDD") at $72.00? So sollee, so vely sollee. Me likee velly muchlee.
OT, but have you been following TROV? It has/is having quite a run on various news. I would appreciate any insights that you could offer. Many thanks.
Suntrust a highly regarded regional bank; its brokerage subsidiary, R-H, is likewise a well-respected, previously independent concern. The only thing that's noteworthy is their initiation of coverage. Doesn't make sense. Wild guess: a cancer patient connected to the Suntrust corporate family is in a clinical trial and has experienced exceptional results. Again, just a guess.
Makes sense; cash hoard invites such activity.
Depends. I will definitely accumulate additional shares. I think a buyout is likely before too long. It's just a great all around story. For me, there's more risk of being out of the stock than holding it. I don't have the luxury of babysitting it.
Everything's fine; nothing more than short-side price management. Much-a-do-about-nothing, really. Actually, such action only serves to corroborate the good-news narrative.
managing options expiration. Nothing more. Impact/Effect is yielding ever-diminishing returns. Becoming a yawnfest.